CytoSorbents Investor Relations
CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with more than 300,000 CytoSorb® devices sold in more than 70 countries to date, and seeking U.S. FDA market authorization for an investigational product, DrugSorb-ATR®, to remove blood thinning drugs.
Featured News
CytoSorbents
Press Release
CytoSorbents to Participate at the 2026 Jefferies Global Healthcare Conference in London
PRINCETON, N.J., Nov. 9, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that its Chief Executive Officer, Dr. Phillip Chan, and Chief Financial Officer, Mr. Peter Mariani, will attend and participate in one-on-one meetings with investors ... CytoSorbents to Participate at the 2026 Jefferies Global Healthcare Conference in London
CytoSorbents to Report Third Quarter 2026 Financial Results and Recent Business Highlights
PRINCETON, N.J., Oct. 29, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2026 financial results and recent business highlights after the market close on Thursday, November 12, 2026. CytoSorbents’ management will host a live ... CytoSorbents to Report Third Quarter 2026 Financial Results and Recent Business Highlights
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
PRINCETON, N.J., Sept. 30, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces upcoming data presentations using CytoSorb® in open heart surgery at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Barcelona, Spain from October ... CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
PRINCETON, N.J., Sept. 23, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regained compliance with the Nasdaq Stock Market’s minimum bid price requirement of $1.00 per share. CytoSorbents Regains Compliance with Nasdaq Minimum ... CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
